Back to discover
Drug

Mibavademab

Late-stage clinical development
ClassLeptin receptor agonist
RxNorm2540139ChEMBLCHEMBL4650509UNIIPHL2UDY3AB
3
Active clinical trials
Leptin receptor
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Single-Arm, Open-Label, Safety Study in Patients With Generalized Lipodystrophy Switching From Metreleptin to Mibavademab, A Leptin Receptor Agonist Antibody

Clinical trial2026-07-29Status changed to Completed · ClinicalTrials.gov

A Two-Part, Randomized, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Mibavademab in Patients With Generalized Lipodystrophy (LAGO)

Clinical trial2026-07-13Results expected Q2 2028 · ClinicalTrials.gov

A Phase 2, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

Clinical trial2026-06-17Results expected Q3 2027 · ClinicalTrials.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Clinical trial2026-04-02Completed · ClinicalTrials.gov

An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene

Clinical trial2026-03-10Results expected Q2 2027 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Mibavademab
RxNorm CUI
2540139
ChEMBL ID
CHEMBL4650509
UNII
PHL2UDY3AB
Primary mechanism
Leptin receptor agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Leptin receptor
LEPR · P48357
AGONISTLeptin receptor agonist

Clinical trials

5 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
5
registered trials across all phases
LATEST COMPLETION 2026
3
Active studies
3
Recruiting
3
Late-stage (III+)
2
Completed
PHASE DISTRIBUTIONn = 5
Phase 22Phase 33
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials